← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › OTHER ANTIANEMIC PREPARATIONS › Other antianemic preparations
erythropoietin
B03XA01
Forms & Strengths
- Injection: 1000 IU/mL
- Injection: 2000 IU/mL
- Injection: 3000 IU/mL
- Injection: 4000 IU/mL
- Injection: 5000 IU/mL
- Injection: 6000 IU/mL
- Injection: 10000 IU/mL
- Injection: 20000 IU/mL
- Injection: 30000 IU/mL
- Injection: 40000 IU/mL
Adult Dosing
- Chronic kidney disease: 50-100 IU/kg IV/SC 3 times a week
- Anemia in HIV-infected patients: 100-200 IU/kg IV/SC 3 times a week
- Anemia in cancer patients: 150-300 IU/kg IV/SC 3 times a week
- Surgery: 300 IU/kg IV/SC once daily for 10 days before and 4 days after surgery
- Dose adjustments based on hemoglobin levels
Pediatric Dosing
- Chronic kidney disease: 50 IU/kg IV/SC 3 times a week
- Premature infants: 200-400 IU/kg IV/SC 3 times a week
- Pediatric cancer patients: 100-200 IU/kg IV/SC 3 times a week
- Dose adjustments based on hemoglobin levels and clinical response
Indications
- Anemia associated with chronic kidney disease
- Anemia in HIV-infected patients
- Anemia in cancer patients
- Surgical blood conservation
- Anemia of prematurity
Mechanism of Action
- Stimulates erythropoiesis by binding to erythropoietin receptors
- Increases red blood cell production
- Regulates differentiation and survival of erythroid progenitor cells
Contraindications
- Hypersensitivity to erythropoietin or any component
- Pure red cell aplasia
- Uncontrolled hypertension
Adverse Reactions
- Hypertension
- Headache
- Fatigue
- Nausea and vomiting
- Injection site reactions
- Seizures
- Thrombotic events
Drug Interactions
- Increased risk of thrombosis with other thrombogenic agents
- Interaction with iron supplements: monitor iron levels
- Interaction with blood thinners: monitor coagulation parameters
Curated Content: Needs Vetting Before Put to Clinical Use